Table 4 Distribution of Ki-67 labelling index according to gender, stage, type of treatment
Parameters | Ki-67 Labeling Index, n (%) | Total n | ||
|---|---|---|---|---|
≤2 (166 cases) | 3–20 (56 cases) | >20 (6 cases) | ||
Gender | ||||
Male | 82 (74.5) | 24 (21.8) | 4 (3.6) | 110 (100.0) |
Female | 84 (71.2) | 32 (27.1) | 2 (1.7) | 118 (100.0) |
Stage TNM | ||||
Τ0 | 16 (84.2) | 3 (15.8) | 0 (0) | 19 (100.0) |
Τ1 | 68 (82.9) | 14 (17.1) | 0 (0) | 82 (100.0) |
Τ2 | 16 (64.0) | 9 (36.0) | 0 (0) | 25 (100.0) |
Τ3 | 17 (54.8) | 11 (35.5) | 3 (9.7) | 31 (100.0) |
Τ4 | 4 (28.6) | 10 (71.4) | 0 (0) | 14 (100.0) |
ΤΧ | 45 (78.9) | 9 (15.8) | 3 (5.3) | 57 (100.0) |
Ν0 | 111 (78.2) | 30 (21.1) | 1 (0.7) | 142 (100.0) |
Ν1 | 39 (60.9) | 20 (31.3) | 5 (7.8) | 64 (100.0) |
ΝΧ | 16 (72.7) | 6 (27.3) | 0 (0) | 22 (100.0) |
Μ0 | 97 (81.5) | 22 (18.5) | 0 (0) | 119 (100.0) |
Μ1 | 29 (52.7) | 21 (38.2) | 5 (9.1) | 55 (100.0) |
ΜΧ | 40 (74.1) | 13 (24.1) | 1 (1.8) | 54 (100.0) |
Type of treatment | ||||
Lanreotide | 52 (69.3) | 20 (26.6) | 3 (4.1) | 75 (100.0) |
Octreotide | 85 (71.4) | 33 (27.7) | 1 (0.9) | 119 (100.0) |
Sunitinib | 5 (50.0) | 5 (50.0) | 0 (0) | 10 (100.0) |
Everolimus | 3 (60.0) | 2 (40.0) | 0 (0) | 5 (100.0) |
Chemotherapy | 11 (50) | 9 (40.9) | 2 (9.1) | 22 (100.0) |